IRIDEX Corporation

IRIX Healthcare Medical Devices

IRIDEX Corporation’s revenue for fiscal 2025 (year ended December 2025) was $52.7 million, up 8.23% from fiscal 2024. In the quarter to June 2026, revenue fell 7.41%, EPS fell 16.7%, free cash flow grew 130.2% and total debt rose 3.27%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

0.81 0.01 −1.22%
Market cap
$14.5M
P/E
0.0×
Fwd P/E
−21.8×
Dividend yield
—
F-score
4/9
Altman Z
−1.95
Beneish M
−2.75
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Piotroski F-Score
3 3 4 4

+8 more TTM periods

ROE
308.17% 1,574.52% (870.85%) (780.21%)
ROA
(12.06%) (10.48%) (15.22%) (17.39%)
ROIC
(63.07%) (43.09%) (61.12%) (67.92%)
Return on Tangible Assets
(32.34%) (27.53%) (36.66%) (43.49%)
Average Days of Receivables
50.17 58.42 66.14 68.68
Free Cash Flow per Share
(0.11) (0.15) (0.13) (0.23)
Free Cash Flow
(2.00) (2.53) (2.26) (3.99)
Other line items

Show all line items

Columns are period end dates